In its opinion adopted on 16 December 2022 the SCHEER considered 6 scenarios (each including one or more exposure mode: inhalation, oral and dermal) as relevant for the exposure assessment and possibly identifying safe uses for which a derogation could be granted.
Recital 7, Directive (EU) 2026/192
In forcesince 28 Jan 2026